Organogenesis (NASDAQ:ORGO) Stock Price Up 7.3% – What’s Next?

Organogenesis (NASDAQ:ORGO) shares rose 7.3% during trading on Monday . The company traded as high as $4.29 and last traded at $4.29. Approximately 175,286 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 773,580 shares. The stock had previously closed at $4.00.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organogenesis in a report on Monday, December 29th. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $9.00 target price on shares of Organogenesis in a research report on Friday, December 26th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.00.

Organogenesis Stock Performance

The company has a market cap of $494.95 million, a PE ratio of -32.50 and a beta of 1.46. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32. The stock’s 50-day simple moving average is $4.65 and its 200 day simple moving average is $4.69.

Organogenesis (NASDAQ:ORGO) last issued its earnings results on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.11. The business had revenue of $150.86 million for the quarter, compared to the consensus estimate of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. As a group, equities analysts anticipate that Organogenesis will post -0.07 EPS for the current year.

Insider Transactions at Organogenesis

In other Organogenesis news, Director Glenn H. Nussdorf sold 200,000 shares of the business’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the sale, the director directly owned 2,565,591 shares in the company, valued at approximately $13,187,137.74. The trade was a 7.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 500,000 shares of company stock valued at $2,620,120 in the last three months. Corporate insiders own 33.00% of the company’s stock.

Institutional Trading of Organogenesis

Several hedge funds and other institutional investors have recently made changes to their positions in ORGO. Creative Planning boosted its holdings in Organogenesis by 8.2% during the third quarter. Creative Planning now owns 38,279 shares of the company’s stock worth $162,000 after buying an additional 2,887 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Organogenesis by 57.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 14,522 shares of the company’s stock worth $61,000 after acquiring an additional 5,273 shares in the last quarter. Quarry LP purchased a new stake in shares of Organogenesis during the 3rd quarter worth approximately $25,000. State of Alaska Department of Revenue acquired a new stake in shares of Organogenesis in the 3rd quarter worth approximately $25,000. Finally, Flagship Harbor Advisors LLC purchased a new position in Organogenesis in the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.